Core Viewpoint - Edwards Lifesciences Corp. is set to report its second-quarter 2025 results on July 24, with expectations of revenue and earnings declines compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for revenues is $1.49 billion, indicating an 8.9% decline from the prior year's figure [2]. - The estimate for net earnings is 62 cents per share, reflecting an 11.4% decrease from the year-ago reported figure [2]. Estimate Revision Trend - Earnings estimates have remained unchanged at 62 cents per share over the past 60 days, indicating stability in expectations ahead of the earnings announcement [3]. Factors at Play - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform well in the U.S. due to the SAPIEN 3 Ultra RESILIA platform, with a projected revenue of $1.09 billion, representing a 5.2% year-over-year increase [4][5]. - The TMTT segment is anticipated to show significant growth, with revenues estimated at $130.4 million, a 57.1% improvement from the previous year, driven by the PASCAL and EVOQUE systems [6][8]. Segment Performance - The Surgical Structural Heart segment is expected to report revenues of $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter, supported by the global adoption of the RESILIA portfolio [10][11]. - The commercial launch of the EVOQUE tricuspid replacement system is likely to have progressed well, aided by Medicare coverage [7]. Earnings Whispers - Edwards has an Earnings ESP of 0.00%, indicating no advantage in beating estimates this quarter [12]. - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13].

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) technology into three new hospitals, highlighting the increasing recognition of BVA's role in improving patient outcomes and reducing healthcare costs [1][2] - The growth is attributed to the integration of Daxor's CLIA-certified ezBVA Lab service and on-site blood volume analyzers, which are expected to drive accelerated sales growth throughout 2025 as clinicians adopt BVA for fluid management [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at major hospital centers in the U.S., significantly impacting surgical and medical conditions, particularly in reducing mortality and readmissions in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Recent Developments - Recent sales wins include the adoption of ezBVA Lab services in a Tennessee medical center for cardiology applications, integration of BVA with an on-site analyzer in an Arkansas hospital for advanced heart care, and utilization of ezBVA Lab service in a leading referral hospital serving Arizona, Nevada, and Utah for advanced heart failure patients [5]

Core Viewpoint - TELA Bio, Inc. is set to report its second quarter 2025 financial results on August 11, 2025, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The second quarter 2025 financial results will be reported on August 11, 2025 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy while minimizing long-term exposure to synthetic materials [3].

Core Viewpoint - ZimVie Inc. has entered into a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share, representing a 99% premium over its recent trading price, with an enterprise value of approximately $730 million [2][3]. Company Overview - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive portfolio of products aimed at supporting dental tooth replacement and restoration procedures [8]. - The company is headquartered in Palm Beach Gardens, Florida, and is committed to advancing clinical science and technology in the dental sector [8]. Acquisition Details - Under the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share, with the transaction expected to close by year-end 2025, pending customary closing conditions [2][4]. - The Board of Directors of ZimVie has unanimously approved the transaction, which is not subject to a financing condition [4]. - Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ [5]. Strategic Implications - The acquisition is expected to provide ZimVie with the strategic and financial backing necessary to expand its innovative dental technology globally [3]. - ARCHIMED views ZimVie as having strong fundamentals and compelling growth potential, indicating a positive outlook for the company's future [3]. Go-Shop Period - ZimVie has a 40-day go-shop period during which it can solicit proposals from third parties, ending on August 29, 2025 [6]. - There is no assurance that this solicitation process will yield a superior proposal [6]. Advisory Roles - Centerview Partners is serving as the exclusive financial advisor to ZimVie, while UBS Investment Bank is the exclusive financial advisor to ARCHIMED [7].

Core Viewpoint - Abbott Laboratories reported better-than-expected sales and profits for the second quarter but reduced earnings and growth projections for the remainder of the year [1][2]. Financial Performance - Second-quarter sales reached $11.14 billion, surpassing the consensus estimate of $11.07 billion [1]. - Adjusted earnings for the second quarter were $1.26 per share, exceeding the consensus of $1.25 and falling within the management's guidance of $1.23-$1.27 [1]. Growth Projections - For full-year 2025, Abbott narrowed its adjusted earnings guidance from a range of $5.05-$5.25 per share to $5.10-$5.20 per share, compared to the consensus of $5.16 [2]. - The company expects organic sales growth of 7.5%-8.0%, slightly down from the previous guidance of 7.5%-8.5% [2]. Margin Expectations - Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, unchanged from prior guidance but lower than the previous range of 23.5%-24.0% [3]. - The expected adjusted earnings for the third quarter of 2025 are projected to be between $1.28 and $1.32 per share, below the consensus of $1.34 per share [3]. Market Reaction - Following the earnings announcement, Abbott's shares fell by 8.5%, closing at $120.51 [3]. Analyst Ratings - BTIG analyst maintained a Buy rating but lowered the price target from $148 to $145 [5]. - Jefferies analyst upgraded Abbott from Hold to Buy and raised the price target from $143 to $145 [5]. - Mizuho analyst maintained a Neutral rating and reduced the price target from $140 to $135 [5].

Core Insights - Anumana's FDA-cleared LEF algorithm is the first certified third-party solution available through Philips' ECG ecosystem, enhancing cardiac care capabilities [1][3] - The Philips ECG AI Marketplace provides a centralized platform for U.S. hospitals to integrate various AI-powered diagnostic tools, improving workflow and efficiency [2][4] Company Developments - Philips has launched the ECG AI Marketplace, allowing cardiac care teams to access multiple AI tools, which streamlines the diagnostic process and reduces the time for ECG result reviews [2][3] - Anumana's LEF algorithm, which identifies reduced ejection fraction as an early indicator of heart failure, is now integrated into Philips' ECG portfolio, including IntelliSpace ECG and Philips cardiographs [3][4] Industry Impact - The collaboration between Philips and Anumana aims to improve early detection of cardiovascular diseases and enhance patient care through AI diagnostics [3][4] - Anumana's algorithms have been validated in studies involving over 150,000 patients and are supported by nearly 100 peer-reviewed publications, indicating a strong foundation for clinical application [4]

Core Insights - Johnson & Johnson reported Q2 2025 earnings with sales of $23.7 billion, a 4.6% increase, and adjusted EPS of $2.77, with net earnings of $5.5 billion, leading to an increase in full-year sales and EPS guidance [1] - The company is focusing on strategic execution, diversified growth drivers, and pipeline achievements to enhance its long-term investment profile [2] Business Performance - Despite a 43.2% year-over-year revenue decline for Stelara due to biosimilar competition, innovative medicine sales rose 3.8% operationally, and medtech achieved 6.1% operational sales growth, driven by a 22% increase in cardiovascular segment sales [3] - Excluding Stelara, 90% of the business experienced robust growth of 15.5%, with 13 brands achieving double-digit growth, showcasing the company's resilience [4] Oncology Growth Strategy - The oncology franchise saw a 22.3% growth, with a significant portion of multiple myeloma patients using Johnson & Johnson products, and management aims to become the global leader in oncology by 2030 with projected sales exceeding $50 billion annually [5] - The TAR-200 product is expected to significantly outperform market expectations, positioning Johnson & Johnson as a top-tier oncology growth platform [6] MedTech Developments - Medtech's cardiovascular segment achieved 22% sales growth, supported by acquisitions and maintaining its status as the fastest-growing company in the cardiovascular medtech space [7] - The electrophysiology business reported $5 billion in sales with 9.8% growth, benefiting from strong physician adoption and product innovations [8] Future Outlook - Management guided for full-year 2025 sales growth of 5.1%-5.6%, raising the midpoint of sales guidance to $93.4 billion and adjusted EPS guidance to $10.80-$10.90, with key pipeline catalysts expected in the second half of 2025 [9]

BROSSARD, Quebec, July 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian leader in artificial intelligence (AI) for the early detection of retinal and systemic diseases, is proud to announce that it has formally submitted a Pre-Submission (Q-sub) to the U.S. Food and Drug Administration (FDA) for its flagship CARA System. This filing marks the first strategic step toward regulatory clearance and commercial deployment in the U.S ...

Carlsmed, a medical technology company that uses AI to personalize spine surgery, is seeking to raise as much as $107.2 million in a US IPO https://t.co/Z5je1FkV3q ...

Company Leadership Transition - Steven Pfanstiel has been appointed as the new Chief Financial Officer of Neuronetics, effective July 15, 2025, replacing Steve Furlong, who will retire on March 31, 2026 [2][3] - Steve Furlong will continue to serve as Senior Advisor to the CEO during the transition period to ensure operational continuity [2][3] Executive Background - Steven Pfanstiel brings over two decades of healthcare experience, having previously served as CFO and COO at Marinus Pharmaceuticals, where he was instrumental in the launch of the flagship product, Ztalmy [3][4] - Pfanstiel has held senior financial roles at various high-growth healthcare companies, including Lifescan and Optinose, and has experience at Johnson & Johnson across multiple product categories [3][4] Strategic Vision and Growth - Neuronetics aims to expand access to mental health treatments and deliver sustainable growth, leveraging Pfanstiel's expertise in financial leadership and growth strategies [3][4] - The company is focused on integrating Greenbrook operations and achieving positive cash flow in the third quarter of 2025, marking a significant operational milestone [5] Stock Incentives - As part of his employment agreement, Pfanstiel received an inducement grant of 400,000 restricted stock units, with specific vesting schedules tied to his continued employment [4] Company Performance and Market Position - Neuronetics reaffirms its guidance for the second quarter and full year 2025, driven by successful integration efforts and key growth drivers [5] - The company operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD) [6][7]